Margaret Lee points to Z160 precliincal model, but what about NMED-160 preclinicals?
Margaret Lee points to Z160 precliincal model, but what about the NMED-160 preclinicals?
I understand that Merck pursued NMED-160 based on pre-clinical studies which indicates that bioavailability in the preclinical animal models WAS NOT the issue. Now that Zalicus has addressed bioavailability in humans, I want to know why might the nervous system of the lab models failed to translate to humans. Again Margaret Lee points to preclinical models for the upcoming meeting in June in Philadelphia.
There are "limitations, and advantages of about 40 different animal models of neuropathic pain". How can we have confidence that Z160 is simply not effective in the models, REGARDLESS of bioavailability as illustrated by NMED160, and a failure in the context of humans? Strong evidence comes from Prialt. We KNOW it works, and IF Z160 accumulates in CSF, it should work as well.
"Ziconotide (Prialt) is a peptide consisting of 25 naturally-occurring amino acids of the L-configuration, and does not appear to be appreciably metabolised in the CSF."
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy. So, Corrigan obviously thinks Z160 makes it to the CSF in high [ ]
11:10 State-Dependent Calcium Channel Blockers for Pain
Margaret S. Lee, Ph.D., Vice President, Research & Translational Medicine, Zalicus, Inc
With prolonged excitation, such as during chronic pain signaling, the relative proportion of voltage gated calcium channel inactivation increases. Specifically targeting the inactivated state offers an opportunity for pharmacological selectivity that may broaden therapeutic window, minimize adverse effects and increase efficacy. We have discovered novel, first-in-class calcium channel blockers that demonstrate enhanced potency for the inactivated state. Z160 and Z944, selective, state-dependent, N- and T-type calcium channel blockers respectively, demonstrate potent effects in nonclinical pain models. Both are currently in clinical development for pain indication
If Z160 makes it to the CSF in high enough [ ], the next question is Z160 equivalent to Prialt in ion channel coverage. The lab model pain data suggests that it is. Jason Napodano gives Z160 a 20% chance of making it to market. This is a 20 fold premium over the known success rate of 1% stated by former Neuromed CFO Christopher Gallen. Not bad at all!
Based on the reasoning above, Z160 could be a Nobel Prize winner for Terry as he has laid the academic groundwork. He just has not hit the homerun yet. He has the Science publications and is a pioneer.
Pregabalin was invented by medicinal chemist Richard Bruce Silverman at Northwestern University in the United States. Read the history of what success in this field means.
Success of Z160 would justify Terry's Nobel nomination because Z160 would address the growing opioid crisis. Z160 + Z944 would be next, combinations. If Corrigan ordered primate testing, I would go well beyond Jason Napodano's 20% chance of success.
There will be no reverse split as CFO Justin Renz has already stated. ZLCS will transition to the NASDAQ Capital Market instead. This paves the way to the Z160 verdict expected in Q3 or Q4. This is a very clear high risk, high reward investment. We have naysayers on this board, some short and others wanting in at a rock bottom price. The big money is averaging in and will continue to do so.